The 50-pound Argus unit draws air continuously, extracts genetic material and runs shotgun sequencing inside the enclosure. It targets pathogens such as Ebola and anthrax. An ultraviolet trigger flags biological material in seconds, qPCR checks it against known threats, and a first sequencing result arrives in under an hour. Intended sites include airports, mass-transit hubs and military facilities. Pilgrim has signed an agreement with the CDC for an automated airborne biosurveillance system and has begun placing units across the US. Other backers include Peter Thiel and Coinbase co-founder Fred Ehrsam. Anthropic's Logan Graham (head of its Frontier Red Team) and Sholto Douglas invested as individuals, not through the company. The founder, Jake Adler, is a 22-year-old Thiel Fellow. Proceeds go to hardware engineering, biodefense research hiring, and the domestic rollout. The $150M mark is high for a seed round, and Pilgrim itself has not issued a formal announcement. For AI founders, the signal is that concern about model-enabled biological risk is turning into funded physical infrastructure, with government agencies as buyers. Argus still has to prove reliable field detection and win repeat contracts from DHS, the CDC and the Pentagon, where larger defense and diagnostics firms compete. Teams selling AI into biosecurity should expect procurement cycles and hardware validation to matter as much as model quality.